Janus Henderson Group PLC Glycomimetics Inc Transaction History

Janus Henderson Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 31, 2019	SELL	$10.6 - $13.12 $291,945 - $361,351	-27,542 Reduced 2.44%	1,100,747 $13.1 Million
Q1 2019 Apr 30, 2019	SELL	$9.96 - $13.44 $686,761 - $926,714	-68,952 Reduced 5.76%	1,128,289 $14.1 Million
Q4 2018 Feb 06, 2019	BUY	$8.47 - $14.71 $235,050 - $408,217	27,751 Added 2.37%	1,197,241 $11.3 Million
Q3 2018 Nov 09, 2018	SELL	$13.7 - $17.12 $206,048 - $257,484	-15,040 Reduced 1.27%	1,169,490 $16.8 Million
Q2 2018 Aug 10, 2018	SELL	$14.63 - $19.19 $328,267 - $430,585	-22,438 Reduced 1.86%	1,184,530 $19.1 Million
Q1 2018 May 14, 2018	BUY	$16.06 - $25.35 $3.68 Million - $5.81 Million	229,209 Added 23.44%	1,206,968 $19.6 Million
Q4 2017 Feb 09, 2018	BUY	$10.51 - $17.22 $5.15 Million - $8.44 Million	490,259 Added 100.57%	977,759 $16.4 Million
Q3 2017 Nov 14, 2017	SELL	$10.14 - $14.85 $143,298 - $209,860	-14,132 Reduced 2.82%	487,500 $0
Q2 2017 Aug 17, 2017	BUY	N/A	501,632	501,632 $5.6 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.